Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
90 hedge funds and large institutions have $771M invested in Aimmune Therapeutics in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 12 closing their positions.
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
14% more capital invested
Capital invested by funds: $676M → $771M (+$94.5M)
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less funds holding
Funds holding: 92 → 90 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$43.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.1M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$16.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.5M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
+$8.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$29.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.9M |
| 3 |
TG
TLP Group
Evanston,
Illinois
|
-$4.79M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$3.89M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$3.39M |
AIMT Hedge Fund Activity: Q1 2017 in Review
90 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q1 2017, worth a combined $771M — up 14% from $676M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AIMT positions and 12 closed out — a net gain of 3 holders — while 33 added to existing stakes and 29 trimmed.
The largest buyer was BlackRock, adding an estimated $43.9M. The largest seller was Fidelity Investments, cutting an estimated $29.8M.
- 90 institutional investors held Aimmune Therapeutics (AIMT) as of Q1 2017, down from 92 in Q4 2016.
- Funds reported $771M of Aimmune Therapeutics stock for Q1 2017, up 14% quarter-over-quarter.
- 15 funds opened new Aimmune Therapeutics positions in Q1 2017 and 12 closed out, a net change of +3 holders.
- The largest Aimmune Therapeutics buyer in Q1 2017 was BlackRock, an estimated $43.9M added.
- The largest Aimmune Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2017.